The Effect and Safety of 5-HT_1F Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis

Table 2

RRs and 95% CI of patient’s absence of migraine-associated symptoms at 2 h after the first dose.

Comparisons	Nausea-free at 2 h			Vomiting-free at 2 h			Photophobia-free at 2 h			Phonophobia-free at 2 h
		RR (95% CI)			RR (95% CI)			RR (95% CI)			RR (95% CI)
Placebo comparisons
Lasmiditan 50 mg vs. placebo	3	0.99 (0.94, 1.05)	0%	2	1.02 (0.94, 1.11)	72%	3	1.19 (1.04, 1.37)	15%	3	1.13 (1.05, 1.22)	0%
Lasmiditan 100 mg vs. placebo	3	1.04 (1.00, 1.08)	46%	3	1.01 (0.98, 1.04)	81%	3	1.35 (1.17, 1.57)	72%	3	1.16 (1.10, 1.22)	8%
Lasmiditan 200 mg vs. placebo	3	1.03 (0.99, 1.07)	0%	3	1.00 (0.99, 1.01)	0%	3	1.30 (1.21, 1.40)	10%	3	1.16 (1.10, 1.22)	0%
Dosage comparisons
Lasmiditan 50 mg vs. 100 mg	2	0.96 (0.91, 1.01)	0%	2	0.98 (0.94, 1.02)	56%	2	0.91 (0.84, 0.98)	41%	2	0.94 (0.88, 1.01)	18%
Lasmiditan 100 mg vs. 200 mg	3	1.00 (0.97, 1.05)	18%	3	1.01 (0.99, 1.03)	67%	3	1.00 (0.94, 1.05)	19%	3	1.00 (0.96, 1.05)	0%
Lasmiditan 200 mg vs. 50 mg	2	1.02 (0.96, 1.08)	0%	2	1.00 (0.98, 1.02)	0%	2	1.12 (1.04, 1.22)	0%	2	1.06 (0.99, 1.14)	0%

(significant difference). : number of trials; RR: risk ratio; 95% CI: 95% confidence intervals.